Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Breast Cancer

  Free Subscription


Articles published in Mod Pathol

Retrieve available abstracts of 71 articles:
HTML format



Single Articles


    February 2024
  1. AL ASSAAD M, Michaud O, Semaan A, Sigouros M, et al
    Whole-Genome Sequencing Analysis of Male Breast Cancer Unveils Novel Structural Events and Potential Therapeutic Targets.
    Mod Pathol. 2024 Feb 16:100452. doi: 10.1016/j.modpat.2024.100452.
    PubMed     Abstract available


  2. SHAFIQUE A, Gonzalez R, Pantanowitz L, Tan PH, et al
    A Preliminary Investigation into Search and Matching for Tumor Discrimination in World Health Organization Breast Taxonomy Using Deep Networks.
    Mod Pathol. 2024;37:100381.
    PubMed     Abstract available


  3. DERAKHSHAN F, Da Cruz Paula A, Selenica P, da Silva EM, et al
    Nonlobular Invasive Breast Carcinomas with Biallelic Pathogenic CDH1 Somatic Alterations: A Histologic, Immunophenotypic, and Genomic Characterization.
    Mod Pathol. 2024;37:100375.
    PubMed     Abstract available


    January 2024
  4. SIQUEIRA JM, Mitani Y, Hoff CO, Bonini F, et al
    Analysis of B7-H4 Expression Across Salivary Gland Carcinomas Reveals Adenoid Cystic Carcinoma-Specific Prognostic Relevance.
    Mod Pathol. 2024;37:100371.
    PubMed     Abstract available


    December 2023
  5. IBRAHIM A, Jahanifar M, Wahab N, Toss MS, et al
    Artificial Intelligence-Based Mitosis Scoring in Breast Cancer: Clinical Application.
    Mod Pathol. 2023 Dec 26:100416. doi: 10.1016/j.modpat.2023.100416.
    PubMed     Abstract available


  6. LI X, Lee JH, Gao Y, Zhang J, et al
    Correlation of HER2 Protein Level with mRNA Level Quantified by RNAscope in Breast Cancer.
    Mod Pathol. 2023 Dec 20:100408. doi: 10.1016/j.modpat.2023.100408.
    PubMed     Abstract available


  7. IBRAHIM A, Toss MS, Alsaleem M, Makhlouf S, et al
    Novel Two Gene Signature Associated with Breast Cancer Proliferation: Insights from Predictive Differential Gene Expression Analysis.
    Mod Pathol. 2023 Dec 15:100403. doi: 10.1016/j.modpat.2023.100403.
    PubMed     Abstract available


    November 2023
  8. BAEZ-NAVARRO X, van Bockstal MR, Andrinopoulou ER, van Deurzen CHM, et al
    Corrigendum to "HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort" [Modern Pathology 36(4) 100087].
    Mod Pathol. 2023;36:100356.
    PubMed    


  9. LIN LH, Tran I, Yang Y, Shen G, et al
    DNA Methylation Identifies Epigenetic Subtypes of Triple-Negative Breast Cancers With Distinct Clinicopathologic and Molecular Features.
    Mod Pathol. 2023;36:100306.
    PubMed     Abstract available


  10. SHEN S, Ma W, Brown D, Da Cruz Paula A, et al
    HER2 Genetic Intratumor Heterogeneity Is Associated With Resistance to Trastuzumab and Trastuzumab Emtansine Therapy in Recurrent High-Grade Endometrial Cancer.
    Mod Pathol. 2023;36:100299.
    PubMed     Abstract available


    August 2023
  11. RONG R, Sheng H, Jin KW, Wu F, et al
    A Deep Learning Approach for Histology-Based Nucleus Segmentation and Tumor Microenvironment Characterization.
    Mod Pathol. 2023;36:100196.
    PubMed     Abstract available


    July 2023
  12. MAKHLOUF S, Althobiti M, Toss M, Muftah AA, et al
    THE CLINICAL AND BIOLOGICAL SIGNIFICANCE OF ESTROGEN RECEPTOR-LOW POSITIVE BREAST CANCER.
    Mod Pathol. 2023 Jul 18:100284. doi: 10.1016/j.modpat.2023.100284.
    PubMed     Abstract available


  13. HU Y, Jones D, Zhao W, Tozbikian G, et al
    Incidence, Clinicopathologic Features, HER2 Fluorescence In Situ Hybridization Profile, and Oncotype DX Results of Human Epidermal Growth Factor Receptor 2-Low Breast Cancers: Experience From a Single Academic Center.
    Mod Pathol. 2023;36:100164.
    PubMed     Abstract available


    June 2023
  14. ATALLAH NM, Wahab N, Toss MS, Makhlouf S, et al
    Deciphering the Morphology of Tumor-stromal Features in Invasive Breast Cancer Using Artificial Intelligence.
    Mod Pathol. 2023 Jun 26:100254. doi: 10.1016/j.modpat.2023.100254.
    PubMed     Abstract available


  15. BAKER GM, Bret-Mounet VC, Xu J, Fein-Zachary VJ, et al
    Toker Cell Hyperplasia in the Nipple-Areolar Complex of Transmasculine Individuals.
    Mod Pathol. 2023;36:100121.
    PubMed     Abstract available


    May 2023
  16. CHALLA B, Tahir M, Hu Y, Kellough D, et al
    Artificial Intelligence-Aided Diagnosis of Breast Cancer Lymph Node Metastasis on Histologic Slides in a Digital Workflow.
    Mod Pathol. 2023 May 11:100216. doi: 10.1016/j.modpat.2023.100216.
    PubMed     Abstract available


  17. CHRISTGEN M, Kreipe H
    Standardization in the Diagnosis of Invasive Lobular Carcinoma of the Breast.
    Mod Pathol. 2023;36:100163.
    PubMed    


  18. SCHWARTZ CJ, Ruiz J, Bean GR, Sirohi D, et al
    Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior.
    Mod Pathol. 2023;36:100125.
    PubMed     Abstract available


    April 2023
  19. YEONG J, Goh D, Tan TJ, Tan B, et al
    Early Triple-Negative Breast Cancers in a Singapore Cohort Exhibit High PIK3CA Mutation Rates Associated With Low PD-L1 Expression.
    Mod Pathol. 2023;36:100056.
    PubMed     Abstract available


    March 2023
  20. KRISHNAN A, Spegg V, Dettwiler S, Schraml P, et al
    Analysis of the PARP1, ADP-Ribosylation and TRIP12 Triad with Markers of Patient Outcome in Human Breast Cancer.
    Mod Pathol. 2023 Mar 27:100167. doi: 10.1016/j.modpat.2023.100167.
    PubMed     Abstract available


  21. ABELE N, Tiemann K, Krech T, Wellmann A, et al
    Noninferiority of Artificial Intelligence-Assisted Analysis of Ki-67 and Estrogen/Progesterone Receptor in Breast Cancer Routine Diagnostics.
    Mod Pathol. 2023;36:100033.
    PubMed     Abstract available


    February 2023
  22. KHOURY T, Rosa M, Nayak A, Karabakhtsian R, et al
    Clinicopathologic Predictors of Clinical Outcomes in Mammary Adenoid Cystic Carcinoma: A Multi-institutional Study.
    Mod Pathol. 2023;36:100006.
    PubMed     Abstract available


    January 2023
  23. MUELLER S, Grote I, Bartels S, Kandt L, et al
    p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.
    Mod Pathol. 2023;36:100100.
    PubMed     Abstract available


  24. WU S, Yue M, Zhang J, Li X, et al
    The Role of Artificial Intelligence in Accurate Interpretation of HER2 Immunohistochemical Scores 0 and 1+ in Breast Cancer.
    Mod Pathol. 2023;36:100054.
    PubMed     Abstract available


  25. BAEZ-NAVARRO X, van Bockstal MR, Andrinopoulou ER, van Deurzen CHM, et al
    HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort.
    Mod Pathol. 2023;36:100087.
    PubMed     Abstract available


  26. CALHOUN BC, Dabbs DJ
    Lack of Standardization in the Diagnosis of Invasive Lobular Carcinoma of the Breast.
    Mod Pathol. 2023;36:100041.
    PubMed    


  27. ROBBINS CJ, Fernandez AI, Han G, Wong S, et al
    Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry.
    Mod Pathol. 2023;36:100032.
    PubMed     Abstract available


  28. BAEZ-NAVARRO X, van Bockstal MR, Nawawi D, Broeckx G, et al
    Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study.
    Mod Pathol. 2023;36:100009.
    PubMed     Abstract available


    November 2022
  29. CYRTA J, Benoist C, Masliah-Planchon J, Vieira AF, et al
    Breast carcinomas with osteoclast-like giant cells: a comprehensive clinico-pathological and molecular portrait and evidence of RANK-L expression.
    Mod Pathol. 2022;35:1624-1635.
    PubMed     Abstract available


  30. HARBHAJANKA A, Gilmore HL, Calhoun BC
    High-risk and selected benign breast lesions diagnosed on core needle biopsy: Evidence for and against immediate surgical excision.
    Mod Pathol. 2022;35:1500-1508.
    PubMed     Abstract available


    October 2022
  31. SIEGMUND SE, Manning DK, Davineni PK, Dong F, et al
    Deriving tumor purity from cancer next generation sequencing data: applications for quantitative ERBB2 (HER2) copy number analysis and germline inference of BRCA1 and BRCA2 mutations.
    Mod Pathol. 2022;35:1458-1467.
    PubMed     Abstract available


  32. BEAN GR, Najjar S, Shin SJ, Hosfield EM, et al
    Genetic and immunohistochemical profiling of small cell and large cell neuroendocrine carcinomas of the breast.
    Mod Pathol. 2022;35:1349-1361.
    PubMed     Abstract available


  33. VANDERBILT C, Brenn T, Moy AP, Harloe G, et al
    Association of HPV42 with digital papillary adenocarcinoma and the use of in situ hybridization for its distinction from acral hidradenoma and diagnosis at non-acral sites.
    Mod Pathol. 2022;35:1405-1410.
    PubMed     Abstract available


  34. SOONG TR, Dillon DA, Rice-Stitt TL, Wieczorek TJ, et al
    Invasive lobular carcinoma with extracellular mucin (ILCEM): clinicopathologic and molecular characterization of a rare entity.
    Mod Pathol. 2022;35:1370-1382.
    PubMed     Abstract available


    August 2022
  35. DE SCHEPPER M, Vincent-Salomon A, Christgen M, Van Baelen K, et al
    Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer.
    Mod Pathol. 2022 Aug 3. pii: 10.1038/s41379-022-01135.
    PubMed     Abstract available


  36. ZHANG H, Katerji H, Turner BM, Audeh W, et al
    HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles.
    Mod Pathol. 2022;35:1075-1082.
    PubMed     Abstract available


  37. STRADELLA A, Gargallo P, Cejuela M, Petit A, et al
    Genomic characterization and tumor evolution in paired samples of metaplastic breast carcinoma.
    Mod Pathol. 2022;35:1066-1074.
    PubMed     Abstract available


    July 2022
  38. GROTE I, Bartels S, Christgen H, Radner M, et al
    ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer.
    Mod Pathol. 2022 Jul 16. pii: 10.1038/s41379-022-01130.
    PubMed     Abstract available


    June 2022
  39. ACS B, Leung SCY, Kidwell KM, Arun I, et al
    Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study.
    Mod Pathol. 2022 Jun 21. pii: 10.1038/s41379-022-01104.
    PubMed     Abstract available


  40. LUCHINI C, Pantanowitz L, Adsay V, Asa SL, et al
    Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring.
    Mod Pathol. 2022;35:712-720.
    PubMed     Abstract available


  41. BACHERT SE, Jen A, Denison C, Kwait D, et al
    Breast lesions associated with mammographic architectural distortion: a study of 588 core needle biopsies.
    Mod Pathol. 2022;35:728-738.
    PubMed     Abstract available


    May 2022
  42. LASHEN A, Toss MS, Alsaleem M, Green AR, et al
    The characteristics and clinical significance of atypical mitosis in breast cancer.
    Mod Pathol. 2022 May 2. pii: 10.1038/s41379-022-01080.
    PubMed     Abstract available


    April 2022
  43. WEI Y, Ke X, Yu J, Jing Q, et al
    Clinical and genomic analyses of neuroendocrine neoplasms of the breast.
    Mod Pathol. 2022;35:495-505.
    PubMed     Abstract available


  44. JEDRZKIEWICZ J, Sirohi D, Uvejzovic N, Gulbahce HE, et al
    RAI1 alternate probe identifies additional gastroesophageal adenocarcinoma cases as amplified following equivocal HER2 fluorescence in situ hybridization testing: experience from a national reference laboratory.
    Mod Pathol. 2022;35:549-553.
    PubMed     Abstract available


    March 2022
  45. KIM CF, Jou D, Ganor O, Boskey ER, et al
    Prostatic metaplasia and pilar differentiation in gender-affirming mastectomy specimens.
    Mod Pathol. 2022;35:386-395.
    PubMed     Abstract available


    January 2022
  46. SALAMA AM, Hanna MG, Giri D, Kezlarian B, et al
    Digital validation of breast biomarkers (ER, PR, AR, and HER2) in cytology specimens using three different scanners.
    Mod Pathol. 2022;35:52-59.
    PubMed     Abstract available


    December 2021
  47. IBRAHIM A, Lashen AG, Katayama A, Mihai R, et al
    Defining the area of mitoses counting in invasive breast cancer using whole slide image.
    Mod Pathol. 2021 Dec 11. pii: 10.1038/s41379-021-00981.
    PubMed     Abstract available


  48. VAN BOCKSTAL MR, Francois A, Altinay S, Arnould L, et al
    Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study.
    Mod Pathol. 2021;34:2130-2140.
    PubMed     Abstract available


    November 2021
  49. SUN X, Zhai J, Sun B, Parra ER, et al
    Effector memory cytotoxic CD3(+)/CD8(+)/CD45RO(+) T cells are predictive of good survival and a lower risk of recurrence in triple-negative breast cancer.
    Mod Pathol. 2021 Nov 27. pii: 10.1038/s41379-021-00973.
    PubMed     Abstract available


    October 2021
  50. CLOUTIER JM, Kunder CA, Charville GW, Hosfield EM, et al
    Nodular fasciitis of the breast: clinicopathologic and molecular characterization with identification of novel USP6 fusion partners.
    Mod Pathol. 2021;34:1865-1875.
    PubMed     Abstract available


  51. SCHWARTZ CJ, Pareja F, da Silva EM, Selenica P, et al
    Histologic and genomic features of breast cancers with alterations affecting the SWI/SNF (SMARC) genes.
    Mod Pathol. 2021;34:1850-1859.
    PubMed     Abstract available


    September 2021
  52. FERGUSON DC, Mata DA, Tay TK, Traina TA, et al
    Androgen receptor splice variant-7 in breast cancer: clinical and pathologic correlations.
    Mod Pathol. 2021 Sep 30. pii: 10.1038/s41379-021-00924.
    PubMed     Abstract available


    August 2021
  53. D'ALFONSO TM, Ho DJ, Hanna MG, Grabenstetter A, et al
    Multi-magnification-based machine learning as an ancillary tool for the pathologic assessment of shaved margins for breast carcinoma lumpectomy specimens.
    Mod Pathol. 2021;34:1487-1494.
    PubMed     Abstract available


  54. KUBA MG, Murray MP, Coffey K, Calle C, et al
    Morphologic subtypes of lobular carcinoma in situ diagnosed on core needle biopsy: clinicopathologic features and findings at follow-up excision.
    Mod Pathol. 2021;34:1495-1506.
    PubMed     Abstract available


    July 2021
  55. BERGERON A, MacGrogan G, Bertaut A, Ladoire S, et al
    Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations.
    Mod Pathol. 2021;34:1282-1296.
    PubMed     Abstract available


  56. NG CCY, Md Nasir ND, Loke BN, Tay TKY, et al
    Genetic differences between benign phyllodes tumors and fibroadenomas revealed through targeted next generation sequencing.
    Mod Pathol. 2021;34:1320-1332.
    PubMed     Abstract available


  57. GRABENSTETTER A, Alfonso TM, Wen HY, Murray M, et al
    Morphologic and immunohistochemical features of carcinoma involving microglandular adenosis of the breast following neoadjuvant chemotherapy.
    Mod Pathol. 2021;34:1310-1319.
    PubMed     Abstract available


  58. AUNG TN, Acs B, Warrell J, Bai Y, et al
    A new tool for technical standardization of the Ki67 immunohistochemical assay.
    Mod Pathol. 2021;34:1261-1270.
    PubMed     Abstract available


    June 2021
  59. TAY TKY, Tan PH
    Papillary neoplasms of the breast-reviewing the spectrum.
    Mod Pathol. 2021;34:1044-1061.
    PubMed     Abstract available


    April 2021
  60. GINTER PS, Idress R, D'Alfonso TM, Fineberg S, et al
    Histologic grading of breast carcinoma: a multi-institution study of interobserver variation using virtual microscopy.
    Mod Pathol. 2021;34:701-709.
    PubMed     Abstract available


    March 2021
  61. KUBA MG, Lester SC, Bowman T, Stokes SM, et al
    Histopathologic features of breast cancer in Li-Fraumeni syndrome.
    Mod Pathol. 2021;34:542-548.
    PubMed     Abstract available


    February 2021
  62. ALDREES R, Gao X, Zhang K, Siegal GP, et al
    Validation of the revised 8th AJCC breast cancer clinical prognostic staging system: analysis of 5321 cases from a single institution.
    Mod Pathol. 2021;34:291-299.
    PubMed     Abstract available


    January 2021
  63. ALLISON KH
    Prognostic and predictive parameters in breast pathology: a pathologist's primer.
    Mod Pathol. 2021;34.
    PubMed     Abstract available


  64. CIMINO-MATHEWS A
    Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls.
    Mod Pathol. 2021;34.
    PubMed     Abstract available


  65. BROGI E, Krystel-Whittemore M
    Papillary neoplasms of the breast including upgrade rates and management of intraductal papilloma without atypia diagnosed at core needle biopsy.
    Mod Pathol. 2021;34.
    PubMed     Abstract available


  66. PAREJA F, Weigelt B, Reis-Filho JS
    Problematic breast tumors reassessed in light of novel molecular data.
    Mod Pathol. 2021;34.
    PubMed     Abstract available


  67. SOKOLOVA A, Lakhani SR
    Lobular carcinoma in situ: diagnostic criteria and molecular correlates.
    Mod Pathol. 2021;34.
    PubMed     Abstract available


  68. SCHNITT SJ
    Diagnosis of ductal carcinoma in situ in an era of de-escalation of therapy.
    Mod Pathol. 2021;34.
    PubMed     Abstract available


  69. COLLINS LC
    Precision pathology as applied to breast core needle biopsy evaluation: implications for management.
    Mod Pathol. 2021;34.
    PubMed     Abstract available


  70. TAN PH
    Fibroepithelial lesions revisited: implications for diagnosis and management.
    Mod Pathol. 2021;34.
    PubMed     Abstract available


  71. BASKOTA SU, Dabbs DJ, Clark BZ, Bhargava R, et al
    Prosigna(R) breast cancer assay: histopathologic correlation, development, and assessment of size, nodal status, Ki-67 (SiNK) index for breast cancer prognosis.
    Mod Pathol. 2021;34:70-76.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.